hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status

Autor: Raffenne, Jerome, Nicolle, Remy, Puleo, Francesco, Corre, Delphine Le, Boyez, Camille, Marechal, Raphael, Emile, Jean François, Demetter, Peter, Bardier, Armelle, Laurent-Puig, Pierre, Mestier, Louis de, Paradis, Valerie, Couvelard, Anne, VanLathem, Jean Luc, MacKey, John R., Bachet, Jean-Baptiste, Svrcek, Magali, Cros, Jerome
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Zdroj: Cancers
Cancers, Vol 11, Iss 11, p 1808 (2019)
Volume 11
Issue 11
ISSN: 2072-6694
Popis: Gemcitabine is still one of the standard chemotherapy regimens for pancreatic ductal adenocarcinoma (PDAC). Gemcitabine uptake into tumor cells is mainly through the human equilibrative nucleoside transport 1 (hENT1). It was therefore proposed as a potential predictive biomarker of gemcitabine efficacy but reports are conflicting, with an important heterogeneity in methods to assess hENT1 expression. A multicenter cohort of 471 patients with a resected PDAC was used to assess simultaneously the predictive value of the 2 best described hENT1 antibodies (10D7G2 and SP120). Three additional antibodies and the predictive value of hENT1 mRNA were also tested on 251 and 302 patients, respectively. hENT1 expression was assessed in 54 patients with matched primary tumors and metastases samples. The 10D7G2 clone was the only hENT1 antibody whose high expression was associated with a prolonged progression free survival and overall survival in patients who received adjuvant gemcitabine. hENT1 mRNA level was also predictive of gemcitabine benefit. hENT1 status was concordant in 83% of the cases with the best concordance in synchronous metastases. The 10D7G2 clone has the best predictive value of gemcitabine benefit in PDAC patients. Since it is not commercially available, hENT1 mRNA level could represent an alternative to assess hENT1 status.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje